Biology subjects

Hulme, H.

Publications and source records attributed to Hulme, H..

9 recordsLinked to original sources

bioRxiv2026

SMEW: An interactive multi-scale toolkit for cross-condition and network-based analysis of spatial metabolomics data

Spatial metabolomics, measured through mass spectrometry imaging (MSI), provides high-throughput, spatially resolved information on metabolite distributions within tissues, including endogenous metabolites and exogenous compounds. This offers a direct readout of cellular biochemical activity and phenotypes, not fully captured by transcriptomics or proteomic profiling. However, inferring biologically meaningful patterns from noisy, high-dimensional MSI data, particularly across multiple samples and complex experimental designs, remains challenging, and often requires substantial programming expertise. Here we introduce SMEW (Spatial Metabolomics Enhanced Workflow), a flexible, interactive and shareable Shiny-based platform designed to enable code-free downstream analysis of spatial metabolomics MSI data. SMEW provides a unified environment for hierarchical analysis across bulk-, region- and pixel-level resolutions, allowing comparisons between experimental conditions like disease or treatment groups while highlighting coherent metabolic patterns and linking these patterns to biological pathways. The workflow leverages local spatial covariation to robustly summarise MSI data through dimensionality reduction, clustering and identification of spatially variable metabolites. In addition, metabolite co-localisation and covariation network analysis, together with spatially resolved pathway enrichment facilitate the biological interpretation of cross-condition datasets within a single integrated interface. SMEW is applicable across MSI technologies and mass resolutions, as illustrated through case studies on DESI and MALDI-ToF datasets from lung, liver, and kidney. By complementing existing MSI processing and visualisation tools with an accessible, multi-sample, and biologically interpretable analysis framework, SMEW enables functional, flexible, rigorous and intuitive exploration of spatial metabolomics datasets. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=84 SRC="FIGDIR/small/721059v1_ufig1.gif" ALT="Figure 1"> View larger version (29K): org.highwire.dtl.DTLVardef@1e2abaeorg.highwire.dtl.DTLVardef@753ee9org.highwire.dtl.DTLVardef@1756fc1org.highwire.dtl.DTLVardef@fbedc7_HPS_FORMAT_FIGEXP M_FIG C_FIG Key PointsO_LISMEW provides a flexible, interactive and shareable Shiny-based platform designed to enable code-free downstream analysis of spatial metabolomics MSI data C_LIO_LIThe SMEW framework enables hierarchical analysis at bulk-, region- and pixel levels within a unified framework without relying on extensive programming expertise C_LIO_LIThe pipeline integrates spatially aware clustering, pathway analysis and identification of metabolite co-localisation modules C_LIO_LIThe workflow facilitates flexible comparison of multi-sample experimental conditions through multivariate modelling, differential testing and covariation networks to study treatment- and disease-associated metabolite dynamics C_LIO_LISMEW has been applied to interrogate diverse biological questions, including characterising disease-associated remodelling in a mouse bleomycin model of pulmonary fibrosis, exploring the therapeutic index of antisense oligonucleotides in the liver and assessing metabolic heterogeneity in a small molecule-treated mouse renal tumour model C_LI

bioinformatics↗

bioRxiv2025

Inhibition of systemic mammalian metabolism by carnitine mimics from the gut microbiota

BackgroundThe gut microbiota and microbiome-derived metabolites are implicated in various aspects of human health. Here we sought to determine the systemic effects, and mechanism of action, of microbiome-derived carnitine analogues in germ free and conventionally colonised mice. ResultsHere we report the systemic localization of the microbiome-derived carnitine analogues, 3-methyl-4-(trimethylammonio)butanoate (3M-4-TMAB) and 5-aminovalerate betaine (5-AVAB), post-administration to germ free mice, with systemic carnitine depletion and mitochondrial dysregulation, reflected in altered acylcarnitine profiles due to incomplete carnitine-mediated fatty acid oxidation. Studies on the inhibitory potency of 3M-4-TMAB at the enzymatic, cellular, and organism levels indicate that, in part, this is a result of inhibition of gammabutyrobetaine hydroxylase, which catalyses the final step in carnitine biosynthesis. Systemic administration of 13C- labelled 3M-4-TMAB to conventionally colonised animals to further investigate the physiological relevance of this inhibition, identified a significant reduction in systemic carnitine levels due to increased excretion in urine and faeces and disruption of carnitine-mediated metabolism across ten organs. ConclusionsThese results highlight the physiological relevance and significance of microbiome-derived metabolites in vivo. The depletion of carnitine and inhibition of its function have potentially long-term impacts on both mammalian energy generation and the protective, signalling and immune regulatory effects of this critical molecule.

microbiology↗

bioRxiv2025

Mapping gene expression across the microbiome-gut-brain axis of germ- and specific pathogen-free mice

Perturbation of the gut microbiota has been implicated in neurological diseases via communication across the microbiome-gut-brain axis. As a result, the discovery of mechanisms underlying interaction across this axis are becoming increasingly important. The germ-free (GF) mouse model has enabled an improved understanding of the influence of the gut microbiota on brain development and function. By utilising an advanced spatial profiling approach, we determined transcriptional changes in the brain, improving our understanding of how brain cells function and interact within their microenvironment in the absence of microbiome influence. Targeted regions of interest were selected based on brain regions implicated in neurological disease or reported structural differences between GF mouse brains and those of colonized mice. In the hippocampus 276 differentially expressed genes (DEGs) were identified, 345 DEGs in the thalamus, and 21 DEGs in pons. Contrastingly we identified only 2 DEGs in the midbrain and 4 in the medulla oblongata, with no DEGs in the cerebellum or corpus callosum. This data provides an overview of gut microbiota influence on gene expression in the brain, highlighting multiple genes of interest for further investigation in the context of microbiome influence on brain function and their potential relevance to neurological disease.

microbiology↗

bioRxiv2024

Spatial mapping of dextran sodium sulphate-induced intestinal inflammation and its systemic effects

Inflammatory bowel disease (IBD) is a multifactorial disease and patients frequently experience extraintestinal manifestations affecting multiple sites. Causes of systemic inflammation remain poorly understood but molecules originating from the intestine likely play a role, with microbial and host small molecules polarizing host immune cells towards a pro- or anti-inflammatory phenotype. Using the dextran sodium sulphate (DSS) mouse model, which mimics the disrupted barrier function, microbial dysbiosis and immune cell dysregulation of IBD, we investigated metabolomic and phenotypic changes at intestinal and systemic sites. Using spatial biology approaches we mapped distribution and relative abundance of molecules and cell types across a range of tissues revealing significant changes in DSS-treated mice. Molecules identified as contributing to the statistical separation of treated from control mice were spatially localized within organs to determine their effects on cellular phenotypes through imaging mass cytometry. This spatial approach identified both intestinal and systemic molecular drivers of inflammation, including several not previously implicated in inflammation linked to IBD or the systemic effects of intestinal inflammation. Metabolic and inflammatory pathway interplay underpins systemic disease and determining drivers at the molecular level may aid the development of new targeted therapies.

molecular biology↗

bioRxiv2024

Genomic diversity of novel strains of mammalian gut microbiome derived Clostridium XIVa strains is driven by mobile genetic element acquisition

Despite advances in sequencing technologies that enable a greater understanding of mammalian gut microbiome composition, our ability to determine a role for individual strains is hampered by our inability to isolate, culture and study such microbes. Here we describe highly unusual Clostridium XIVa group strains isolated from the murine gut. Genome sequencing indicates that these strains, Clostridium symbiosum LM19B and LM19R and Clostridium clostridioforme LM41 and LM42, have significantly larger genomes than most closely related strains. Genomic evidence indicates that the isolated LM41 and LM42 strains diverge from most other Clostridium XIVa strains and supports reassignment of these groups at genus-level. We attribute increased C. clostridioforme LM41 and LM42 genome size to acquisition of mobile genetic elements including dozens of prophages, integrative elements, putative group II introns and numerous transposons including 29 identical copies of the IS66 transposase, and a very large 192 Kb plasmid. antiSmash analysis determines a greater number of biosynthetic gene clusters within LM41 and LM42 than in related strains, encoding a diverse array of potential novel antimicrobial compounds. Together these strains highlight the potential untapped microbial diversity that remains to be discovered within the gut microbiome and indicate that, despite our ability to get a top down view of microbial diversity, we remain significantly blinded to microbe capabilities at the strain level.

microbiology↗

bioRxiv2022

The heterogeneous distribution of extracellular adenosine reveals a myeloid-dependent axis, shaping the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. It has been suggested that the adenosine pathway contributes to the ability of PDAC to evade the immune system and its resistance to immunotherapies (Immuno-Oncology Therapy, IOT), by generating extracellular adenosine (eAdo). Using genetically engineered allograft models of PDAC in syngeneic mice with differential immune infiltration and response to IOT, we showed enrichment of the adenosine pathway in tumour-infiltrating immune cells (in particular, myeloid populations). Using MS-Imaging, we showed that extracellular adenosine distribution is heterogeneous in tumours, with high concentrations in hypoxic margins that surround necrotic areas, associated with a rich myeloid infiltration, demonstrated using Imaging Mass Cytometry (IMC). Pro-tumorigenic M2 macrophages express high levels of the Adora2a receptor; particularly in the IOT resistant model. Blocking the in vivo formation and function of eAdo (Adoi), using a combination of anti-CD73 antibody and an Adora2a inhibitor slowed tumour growth and reduced metastatic burden. In addition, blocking the adenosine pathway improved the efficacy of combinations of cytotoxic agents or immunotherapy. Finally, Adoi remodelled the tumour microenvironment (TME), as evidenced by reduced infiltration of M2 macrophages and Tregs. RNAseq analysis showed that genes related to immune modulation, hypoxia and tumour stroma were downregulated following Adoi and a specific adenosine signature derived from this is associated with a poorer prognosis in patients with PDAC. The formation of eAdo appears to promote the development of the immunosuppressive TME in PDAC, contributing to its resistance to conventional and novel therapies. Therefore, inhibition of the adenosine pathway may represent a strategy to modulate the stroma and improve therapy response in patients with PDAC.

cancer biology↗

bioRxiv2020

Microbiome-derived metabolites reproduce the mitochondrial dysfunction and decreased insulin sensitivity observed in type 2 diabetes

Diabetes is a global health problem that was estimated to be the 7th leading cause of death worldwide in 2016. Type 2 diabetes mellitus (T2DM) is classically associated with genetic and environmental factors, however recent studies have demonstrated that the gut microbiome, which is altered in T2DM patients, is also likely to play a significant role in disease development. Despite this, the identity of microbiome-derived metabolites that influence T2DM onset and/or progression remain elusive. Here we demonstrate that a serum biomarker for T2DM, previously of unknown structure and origin, is actually two microbiome-derived metabolites, 3-methyl-4-(trimethylammonio)butanoate (3M-4-TMAB) and 4-(trimethylammonio)pentanoate (4-TMAP). These metabolites are produced by the Lachnospiraceae family of bacteria, which are highly prevalent in the gut microbiome of T2DM patients and are associated with high dietary fat intake. Treatment of human liver cells with 3M-4-TMAB and 4-TMAP results in a distinct change in the acylcarnitine profile in these cells and significantly reduced their insulin sensitivity; both indicators of T2DM. These results provide evidence of a mechanistic link between gut microbiome derived metabolites and T2DM.

microbiology↗

bioRxiv2020

Monocytes mediate Salmonella Typhimurium-induced tumour growth inhibition

The use of bacteria as an alternative cancer therapy has been re-investigated in recent years. A number of bacterial strains for this purpose have been generated, one of which is SL7207: an auxotrophic Salmonella enterica serovar Typhimurium aroA mutant with immune-stimulatory potential. Here we show that systemic administration of SL7207 induces melanoma tumour growth arrest in vivo, with greater survival of the SL7207-treated group compared to control PBS-treated mice. Administration of SL7207 is accompanied by a change in the immune phenotype of the tumour-infiltrating cells towards pro-inflammatory, with expression of the TH1 cytokines IFN-{gamma}, TNF-, and IL-12 significantly increased. Interestingly, Ly6C+MHCII+ monocytes were recruited to the tumours following SL7207 treatment and were pro-inflammatory. Accordingly, the abrogation of these infiltrating monocytes using clodronate liposomes prevented SL7207-induced tumour growth inhibition. These data demonstrate a previously unappreciated role for infiltrating inflammatory monocytes underlying bacterial-mediated tumour growth inhibition. This information highlights a novel role for monocytes in controlling tumour growth, contributing to our understanding of the immune responses required for successful immunotherapy of cancer.

immunology↗

bioRxiv2020

Mapping the influence of the gut microbiota on small molecules in the brain through mass spectrometry imaging

BackgroundThe gut microbiota is known to influence virtually all facets of human health. Recent work has highlighted a potential role for the gut microbiota in neurological health through the microbiome-gut-brain axis. Microbes can influence the brain both directly and indirectly; through neurotransmitter production, induction of host immunomodulators, or through the release or induction of other microbial or host molecules. MethodsHere we used mass spectrometry imaging (MSI), a label-free imaging tool, to map the molecular changes that occur in the murine gut and brain in germ-free, antibiotic-treated and control mice. ResultsWe determined the spatial distribution and relative quantification of neurotransmitters and their precursors across brain and gut sections in response to the microbiome. Using untargeted MSI of small molecules, we detected a significant change in the levels of four identified metabolites in the brains of germ-free animals compared to controls; vitamin B5, 3-hydroxy-3-methylglutaric acid, 3-methyl-4-(trimethylammonio)butanoate and 4-(trimethylammonio)pentanoate. However, antibiotic treatment induced no significant changes in these metabolites in the brain after one week of treatment. ConclusionsThis work exemplifies the utility of MSI as a tool in determining the spatial distribution and quantification of bacterial and host metabolites in the gut and brain whilst also offering the potential for discovery of novel mediators of microbiome-gut-brain axis communication.

microbiology↗